The compounds are useful for the treatment of diseases associated with the receiver of the LRRK2, for example Parkinsons disease.Claim 1: compounds of the formula (1) or pharmaceutically acceptable salts thereof, in which M is a number from 0 to 3 X is nr\u1d43: - - - - or or - S (o) \u02b3 -In which R is a number from 0 to 2 and r\u1d43 is Hydrogen or alkyl c\u2081\u208b\u2086 r\u00b9 is: rent c\u2081\u208b\u2086 alquenilo c\u2082\u208b\u2086 alquinilo c\u2082\u208b\u2086 haloalquilo c\u2081\u208b\u2086 (c\u2081\u208b\u2086 alkyl alkoxy) - c\u2081\u208b\u2086 Hydroxy alkyl amino alkyl c\u2081\u208b\u2086 c\u2081\u208b\u2086 (alquilsulfonil c\u2081\u208b\u2086 alq) Uilo c\u2081\u208b\u2086 c\u2083\u208b\u2086 cycloalkyl optionally replaced by c\u2081\u208b\u2086 alkyl or Halogen (cicloalquil c\u2083\u208b\u2086) alkyl c\u2081\u208b\u2086,Whose portion is c\u2083\u208b\u2086 cycloalkyl optionally substituted by alkyl c\u2081\u208b\u2086 tetrahidropiranilo tetrahidrofuranilo tetrahidrofuranil c\u2081\u208b\u2086 alkyl or alkyl oxetanilo Oxetanil c\u2081\u208b\u2086 or r\u00b9 and r\u1d43 along with ATOMS, which are United, they form a Ring D And three to six Links can optionally include an additional heteroatom selected from o, N and S,And is replaced by c\u2081\u208b\u2086 oxo Halogen or alkyl, halogen, alkoxy R\u00b2 is: c\u2081\u208b\u2086 cyano alquinilo c\u2082\u208b\u2086 alquenilo c\u2082\u208b\u2086 haloalquilo c\u2081\u208b\u2086 Halo - alkoxy c\u2081\u208b\u2086 c\u2083\u208b\u2086 cycloalkyl, optionally substituted cycloalkyl c\u2083\u208b\u2086 whose portion is in C\u2081\u208b\u2086 alkyl (alkyl c\u2081\u208b\u2086, cicloalquil c\u2083\u208b\u2086)Whose portion is c\u2083\u208b\u2086 cycloalkyl optionally substituted by alkyl c\u2081\u208b\u2086 tetrahidrofuranilo tetrahidrofuranil alkyl c\u2081\u208b\u2086 acetyl oxetanilo or Oxetanil alkyl c\u2081\u208b\u2086 r\u00b3\u1d43 is: - or\u2074 Halogen cyano c\u2081\u208b\u2086 alkyl, cycloalkyl haloalquilo c\
